clinical recent you, thank you Nant will and by call today's investment After and will all from I that, our open Thank review results, highlighting then call Capital, development upcoming milestones. our our discussing start Q&A. for achievements before for joining program, the our Sue us. we financial
promissory is from mentioned, significant loan X The As million convertible strategic of our Nant recent notes. Capital. loan commitment development consists a of $XX tranches
financial was by the is amount the just on gross it the an pathways immune to tranche XX, first difficult system treat fund pancreatic of second an is to the potential million in XX, activation the extremely evolutionary more of customary October commitment as cancer, a expected funded a $X.XX November of million in of metabolic to and orchestrating tranche cancer. to the and subject condition.
This address patient's than amount $X.XX investment, approach gross represents The
pathway Our ways activation cell technology. lead the that could target killer outcomes. assets, in powerful and ivospemin, immunotherapy create enhancing killer T patient The metabolic eflornithine polyamine could and natural pathway platforms and synergies Flynpovi, of cell complement in ImmunityBio's combination
potentially Patrick platforms. potential of activity. especially our believe synergistic the biology approach confidence reset potential antitumor in strategic between of We're the and multi-targeted reflects Dr. to the Soon-Shiong's investors' by We this dysregulated encouraged recognition the investment enhance
of combining eflornithine fight surgeon Flynpovi. validates We're the about as and approaches and ivospemin, regarding of particularly excited in these Nant perspective against ImmunityBio His potential and cancer. our lead innovative assets, our a Capital both approach, impact our leader
gemcitabine ASPIRE III pancreatic the SBP-XXX, study and for This on ductal of global an ivospemin, nab-paclitaxel pivotal our provide with Phase me lead evaluates update let treatment our combination clinical first-line Now or program, candidate, trial. adenocarcinoma. in metastatic
continued have profile Data As our and safety announced many of expand observed through database consistent we're know, substantially Monitoring XXXX, that as with pleased Board, The been the or the approximately taken to remarkable, safety achieving full strong rate. quarter throughout has Safety DSMB you has anticipate a place. engagement with faster-than-expected meetings driving XXX progression trial second patients We of XXXX. enrollment by site enrollment
a than analysis our patients than of Regarding survival experiencing analysis, extended as observe XXXX. initially mentioned first lower event time to led the of of to potentially line our we've interim of rate signaling projected, we trend This persistent timing the better notably interim has that expected. quarter outcomes continue before, time be may
short of the becomes this remains treatment a X.X-month with all know, the landscape. median a when survival X still therapies we And Metastatic survival effective as prognosis, to carry consider which showed advances cancer Even devastating recent we current urgent modest significant falling continues for with pancreatic particularly more need like clear. year. benefit, NALIRIFOX,
encouraging cancer of The observed represent could significance. signals, benefits, takes significant trial the event consideration. well potential these pancreatic over lower FDA If a for far us combined ASPIRE for advance signals treatment, survival ivospemin with into rate regulatory positions in current so we've future meaningful The translate on early standards current environment added care. our
could look months those The forward with for next the by highest disease. which few to challenging pancreatic results, this We and remain leading cancer potentially patients. urgent first driven this focused the be treatment on quarter sharing XXXX need crucial, analysis our to executing of interim the reshape paradigm will trial standards, we
FAP program. our to Turning
final help prepare review, while stages finalize with regulatory for to worked opinion to protocol to have agencies the maximize for evaluating in submit to to forward We the leaders as advancing review. protocol, we look is opportunities We key the the the potential. which program's
Flynpovi, this the trial, has high-risk for enrollment. preventing colorectal Regarding III of many primary cancer, adenoma study PACES and second as completed know, Phase
planned for As study, we before, successfully by cancer. mentioned anticipate XXXX. of the X second colorectal X has treated impact by SWOG, we've having previously for the to the passed readout This futility treatment the analysis, half NCI-supported through Stages data conducted potential landscape patients
first programs. Phase the continue in confidence WorldMeds' has significant This The US II monetization, a polyamine-focused progress our approach. therapy additional provided polyamine-targeted cancer. value eflornithine, as program validation our eflornithine In neuroblastoma we see to marking milestone pediatric with FDA multiple our in portfolio, FDA-approved across through of approval strengthens
castration-resistant Our all X centers Phase actively recruiting, in metastatic The actively JDRF, trial, prostate type in X with II School and clinical Indiana while expand. programs cancer of next with University has expected year. is continue our interim collaboration study Medicine analysis eflornithine an diabetes to enrolling
Hopkins ivospemin John foundation with School polyamine Medicine, in immune and modulators. data cancer, progressing with ovarian preclinical of AACR strong at anticipated. trial encouraging II a in Phase provides we metabolism evaluate prepare planned to is combination our platinum-resistant in ahead, University The as presented as of Looking collaboration ivospemin
first cell being Moving in escalation is report STKXX prestigious This Moffitt study for to the lung at Cancer CPP-XX program. Center. our non-small conducted to cancer. I'm mutant study Phase enrolled pipeline that the in I September, the of late patient we pleased dose
The safety Phase tolerated key eflornithine this on points sachets maximum focused with evaluating determining of X the KEYTRUDA, initial and objective in program dose profile. the combination are
data by mid-XXXX, in II We later the targeted and expect readout initiation Phase is XXXX.
tumors, Dr. particularly investigator. Gray, levels. of recent Thoracic especially in excellent typically new with neuroblastoma. especially Moffitt's principal Department STKXX chairs success under are who reduced T which our immunotherapy, These CPP-XX Dr. is combination approaches Oncology, critical for clinical program for the recognizes as mutant I'm objectives with need trial cell by being leadership leadership. meaningful following Jhanelle Gray's show encouraged antitumor executed This
cell in and explore eager response, responds lung poorly patients, clinically historically reinvigorate could to checkpoint cancer potentially that immune a to population non-small data suggests we're this preclinical inhibitors. Our mutant STKXX polyamine modulation the
Looking safety advance to we'll evaluate we in establish efficacy. ahead, Phase to once II I, Phase
potential excited we're exploring eflornithine combination about trial, including specific other this immunotherapies, role therapy. with and ivospemin's Beyond CAR-T in
Turning pancreatic to neoadjuvant program. our
progress We continue to investigator-initiated opening toward trial. this
development continue also efforts Anderson Cancer to Center. through MD ongoing promise, show with our particularly preclinical collaboration Our
our evaluating our antibodies. remains cancer approaches, the synergies initiative treatment T-cell focused to polyamine research therapy treatment strategy to continue immunotherapy complement preclinical broader This approaches. our and CAR between on including monoclonal studies innovative advanced potential metabolic and inhibitor bispecific clinical reinforce commitment and These
eflornithine's with premalignant conditions. presentation Week focused Disease at presentations, in collaboration Building insights. on Their Vanderbilt generate conference earlier evaluation valuable gastric University Center Digestive this our year on to research continues Medical earlier
our pathway important IIa eflornithine's particularly approach, in Phase treated for demonstrated and patients findings findings, risk of to safety polyamine damage reduce results high The DNA efficacy continue These cancer. showing trial ability validate at especially developing to infection-associated patients. gastric
our targeting look The study collaborative in relevant, developments polyamine these as data prevention advance to forward both in we understanding from sustained pathway We're of particularly research remains momentum efforts and the cancer treatment settings. in these further and NCI-funded this encouraged by programs.
remaining from strategic and second advancements Panbela, trial quarter feedback. enrollment and survival new submitting the a to well in XXXX, marked the as cell Nant late and clinical trial pancreatic In Most XXXX we combine natural XXXX third cancer commitment loan registration metabolic anticipate milestones representing neoadjuvant in and subsequent the open relationship. Phase XXXX, steps the the ovarian killer first And technology. been completion open October, for the in important early EMA to alliance of but XXXX we protocol anticipated in the not closing, trial by platform as for necessary of our summary, polyamine with and of overall inhibitor secured in notably, analysis significant clinical looks T to to early the $XX cell killer include: for XXXX.
In global a the the million II just financial Capital quarter finalizing FAP backing, powerful period completing their interim a III our in have FDA that activation our quarter ASPIRE Phase strategic clinical
opens Soon-Shiong's our regarding possibilities strategy and endorsement cancer Flynpovi, in approach, Dr. the Patrick validates eflornithine of metabolic our and against conditions. ivospemin particularly and synergistic fight new and
of this pipeline, robust we've advancing creation. we momentum potential. strategic XXXX, coupled enhance positions us value therapeutic our through the we progress our The final built, remain leveraging to with clinical the As partnership alliance, quarter and strongly move continued while new focused on for
now turn the results. financial Sue call will over to I discuss our to Sue?
